At-Home Stool Tests: Which Ones Have Been Validated

“At-home stool test” covers two categories that have almost nothing in common except the sample.

One category has published accuracy data against colonoscopy or histology, national recommendation statements behind it, and a defined clinical action attached to a result. The other returns a report on the composition of your microbiome with dietary and supplement suggestions attached. Sorting your kit into the right category is most of the work.

The validated category, and what its numbers look like

Colorectal cancer screening is the clearest example of a stool test that earns its place.

The US Preventive Services Task Force recommends screening for colorectal cancer in all adults aged 50 to 75 as an A recommendation, and in adults aged 45 to 49 as a B recommendation. For adults aged 76 to 85 who have been screened before, it advises that clinicians selectively offer screening, since the net benefit across the whole age group is small. The Task Force concludes with high certainty that screening adults aged 50 to 75 has substantial net benefit, and with moderate certainty that screening adults aged 45 to 49 has moderate net benefit. Adults who have never been screened are more likely to benefit.¹

The context is worth carrying: colorectal cancer is the third leading cause of cancer death for both men and women in the US, an estimated 10.5 percent of new cases occur in people younger than 50, and incidence in adults aged 40 to 49 rose by almost 15 percent from 2000 to 2002 compared with 2014 to 2016. In 2016, 26 percent of eligible US adults had never been screened, and in 2018, 31 percent were not up to date.¹

Stool-based options are among the strategies the Task Force covers, and their performance has been measured directly. A prospective study evaluated a next-generation multitarget stool DNA test in 20,176 asymptomatic adults aged 40 or older who were undergoing screening colonoscopy, so every participant’s stool result could be checked against what the colonoscopy found. Among them, 98 had colorectal cancer, 2,144 had advanced precancerous lesions, 6,973 had non-advanced adenomas, and 10,961 had non-neoplastic findings or a negative colonoscopy.²

Sensitivity for colorectal cancer was 93.9 percent, with a 95 percent confidence interval of 87.1 to 97.7. Specificity for advanced neoplasia was 90.6 percent. Sensitivity for advanced precancerous lesions was 43.4 percent, and specificity for non-neoplastic findings or negative colonoscopy was 92.7 percent. In the same study, a commercially available fecal immunochemical test had a sensitivity of 67.3 percent for colorectal cancer and 23.3 percent for advanced precancerous lesions.²

That is what a validated at-home stool test looks like: a specific question, a reference standard, and numbers for how often it is right and wrong.

Note also that sensitivity for advanced precancerous lesions was 43.4 percent. Even a well validated test can be strong for one target and much weaker for another, which is why “the test was negative” is a statement that needs a follow-up question about negative for what.

The other validated one: fecal calprotectin

Fecal calprotectin is an inflammatory marker released mainly from gastrointestinal granulocytes and measured in a stool sample. Levels have proven reliable for intestinal inflammation with good clinical sensitivity, which is why it is used in screening and monitoring inflammatory bowel disease and in the differential diagnosis between inflammatory bowel disease and irritable bowel syndrome.⁶ That last use matters here because the symptoms of the two often overlap.³

A systematic review with meta-analysis included 17 studies covering 1,956 patients, using colonoscopy with histology or radiology as the reference standard in adults. Summary sensitivity was 85.8 percent, with a 95 percent confidence interval of 78.3 to 91, and specificity was 91.7 percent, with an interval of 84.5 to 95.7.³

The most instructive figures in that paper are the predictive values. At an inflammatory bowel disease prevalence of 1 percent, the negative predictive value was 99.8 percent while the positive predictive value was only 9 percent.³

In a low-prevalence setting, a negative calprotectin is highly reassuring and a positive one is mostly not informative on its own. That asymmetry is a property of prevalence, not of the assay, and it applies to every test used in a population where the condition is rare. The authors also record that all included studies were at high or unclear risk of bias, and that sensitivity was higher in Western than Eastern countries, at 88 against 73 percent.³

The consumer microbiome category

Direct-to-consumer gut microbiome kits arrive in a similar envelope and are a different product entirely.

In 2026, researchers including scientists at the National Institute of Standards and Technology evaluated seven direct-to-consumer gut microbiome testing services using a standardized NIST-developed human fecal material, meaning every service received effectively the same sample.⁴

The results revealed major discrepancies both within and across service providers. The single most damaging finding is a comparison: variability between providers was on the same scale as the biological variability between different donors. In other words, sending one person’s stool to two companies could produce as much difference as sending two different people’s stool to one. The authors attribute the differences to methodological variability and a lack of sufficient quality control, and state that analytical performance is a prerequisite for making sound clinical recommendations.⁴

They also note the positioning problem: these tests straddle the line between more strictly regulated medical devices and minimally regulated general health and wellness products, a distinction that may not be readily apparent to consumers.⁴

Why the regulatory gap persists

A 2025 legal and policy analysis, grounded in a study of direct-to-consumer microbiome testing company websites and their practices, describes those practices as often misleading to consumers and states that the tests lack analytical and clinical validity, meaning they may produce many false positives or false negatives that can harm consumers who rely on them to determine their health status.⁵

The gaps it identifies are specific. There is no proficiency testing for these tests under the Clinical Laboratory Improvement Amendments, and they are not regulated by the FDA as medical devices. The FDA has distinguished direct-to-consumer tests from other laboratory developed tests and asserted that they may pose unique risks because they are ordered outside a physician-patient relationship, but has largely left this group alone, likely viewing them as low-risk general wellness tests exempt from device regulation under the software exemptions in a 2016 federal statute. The authors conclude that many of these tests are neither low-risk wellness tests nor within those statutory exemptions, and should be more stringently regulated.⁵

A product can sit next to a validated screening kit, use the same sample and the same envelope, and be governed as a wellness product rather than a diagnostic.

Questions worth asking about any kit

What clinical question does it answer, and what action follows from each possible result? The colorectal cancer and calprotectin examples both have defined answers to this.¹³

What reference standard was it validated against, and in how many people? Twenty thousand participants against screening colonoscopy is a different level of evidence from an internal comparison.²

What are its sensitivity and specificity for the specific thing you care about, not for its headline target? A test can be 93.9 percent sensitive for cancer and 43.4 percent sensitive for advanced precancerous lesions.²

How common is the condition in someone like you? A positive predictive value of 9 percent at 1 percent prevalence is a real result from a well-performing assay.³

Would two labs give the same answer on the same sample? For seven consumer microbiome services measured against one standardized material, the answer was no.⁴

The practical read

Validated stool tests are among the most useful things in this field. They are non-invasive, they can be done at home, and for colorectal cancer screening the recommendation to use one is national and graded.¹

Consumer microbiome kits are a different product with a different evidence base, currently sitting in a regulatory gap that two separate 2025 and 2026 analyses describe as inadequate.⁴⁵ A report from one is not a diagnosis, and a diet or supplement recommendation derived from it rests on a measurement that has not been shown to reproduce between laboratories. Screening decisions and unexplained symptoms both belong with a clinician.